Roche signed a new pact with C4 Therapeutics to develop degrader-antibody conjugates (DACs), blending antibody delivery with targeted protein degradation payloads. The collaboration includes $20 million upfront and commitments that could reach more than $1 billion in milestones across discovery, regulatory, and commercial stages. Roche will select and design antibodies against two undisclosed oncology targets, while C4 supplies its Torpedo platform to engineer the degrader payloads and generate DAC candidates for preclinical work. Roche’s focus includes using antibody targeting to manage specificity and therapeutic-window constraints common to cytotoxic payload strategies. The deal reinforces that large pharma is moving beyond stand-alone ADC or small-molecule degrader approaches toward hybrid modalities designed to address toxicity and resistance constraints.